FDA.reportPublic FDA data

caffeine 100 MG / ergotamine tartrate 2 MG [Migergot]

RxCUI
1293638
RxNorm name
caffeine 100 MG / ergotamine tartrate 2 MG [Migergot]
Term type
SBDC
Status
Active
Updated
2026-10-29 06:02:11

RxNorm Status History#

Status
Active
Source
RXNORM
Current
YES
Release start
062012
Active start
062012
Multiple ingredient
YES
Branded
YES

Ingredients And Strength#

Ingredient, Strength, Base table
IngredientStrengthBaseBasis of strength
100 MG / 1 EACHcaffeine
2 MG / 1 EACHergotamine

Derived Ingredient Concepts#

Ingredient, RxCUI table
IngredientRxCUI
caffeine1886
ergotamine4025

Source Vocabulary Codes#

Code type, Values, Count table
Code typeValuesCountCategory
PRESCRIBABLEY1ATTRIBUTES
RXNAV_STRcaffeine 100 MG / ergotamine tartrate 2 MG [Migergot]1NAMES
RxNorm Namecaffeine 100 MG / ergotamine tartrate 2 MG [Migergot]1NAMES
TTYSBDC1ATTRIBUTES
RxCUI12936381CODES

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 0 matching rows.

No records found.

Drug Classes#

Source, Class ID, Class table
SourceClass IDClassTypeRelationshipDrug concept
ATCN02CAErgot alkaloidsATC1-4ergotamine
ATCD11AXOther dermatologicalsATC1-4caffeine
ATCN06BCXanthine derivativesATC1-4caffeine
FDASPLD004879ErgotaminesCHEMhas_chemical_structureergotamine
FDASPLD014970XanthinesCHEMhas_chemical_structurecaffeine
FDASPLN0000175739Central Nervous System StimulantEPChas_epccaffeine
FDASPLN0000175766Ergotamine DerivativeEPChas_epcergotamine
FDASPLN0000175790MethylxanthineEPChas_epccaffeine
FDASPLN0000175729Central Nervous System StimulationPEhas_pecaffeine
MEDRTD001393AzolesCHEMci_chemclassergotamine tartrate
MEDRTD001393AzolesCHEMci_chemclassergotamine
MEDRTD002110CaffeineCHEMhas_ingredientcaffeine
MEDRTD002219CarbamatesCHEMci_chemclassergotamine tartrate
MEDRTD004878ErgotamineCHEMhas_ingredientergotamine
MEDRTD004878ErgotamineCHEMhas_ingredientergotamine tartrate
MEDRTD005663FuransCHEMci_chemclassergotamine tartrate
MEDRTD018942MacrolidesCHEMci_chemclassergotamine tartrate
MEDRTD018942MacrolidesCHEMci_chemclassergotamine
MEDRTD019888NelfinavirCHEMci_chemclassergotamine tartrate
MEDRTD019438RitonavirCHEMci_chemclassergotamine tartrate
MEDRTD013449SulfonamidesCHEMci_chemclassergotamine tartrate
MEDRTD000033Abortion, ThreatenedDISEASEci_withergotamine tartrate
MEDRTD000788Angina Pectoris, VariantDISEASEmay_diagnoseergotamine tartrate
MEDRTD001049ApneaDISEASEmay_treatcaffeine
MEDRTD003027Cluster HeadacheDISEASEmay_treatergotamine tartrate
MEDRTD003027Cluster HeadacheDISEASEmay_treatergotamine
MEDRTD003327Coronary DiseaseDISEASEci_withergotamine tartrate
MEDRTD003327Coronary DiseaseDISEASEci_withergotamine
MEDRTD004342Drug HypersensitivityDISEASEci_withergotamine tartrate
MEDRTD004342Drug HypersensitivityDISEASEci_withergotamine
MEDRTD004342Drug HypersensitivityDISEASEci_withcaffeine
MEDRTD005221FatigueDISEASEmay_treatcaffeine
MEDRTD006973HypertensionDISEASEci_withergotamine
MEDRTD006973HypertensionDISEASEci_withergotamine tartrate
MEDRTD007674Kidney DiseasesDISEASEci_withergotamine tartrate
MEDRTD007674Kidney DiseasesDISEASEci_withergotamine
MEDRTD008107Liver DiseasesDISEASEci_withergotamine
MEDRTD008107Liver DiseasesDISEASEci_withergotamine tartrate
MEDRTD008881Migraine DisordersDISEASEmay_treatergotamine tartrate
MEDRTD008881Migraine DisordersDISEASEmay_treatergotamine
MEDRTD016491Peripheral Vascular DiseasesDISEASEci_withergotamine tartrate
MEDRTD016491Peripheral Vascular DiseasesDISEASEci_withergotamine
MEDRTD006473Postpartum HemorrhageDISEASEmay_preventergotamine tartrate
MEDRTD006473Postpartum HemorrhageDISEASEmay_treatergotamine tartrate
MEDRTD011247PregnancyDISEASEci_withergotamine tartrate
MEDRTD011247PregnancyDISEASEci_withergotamine
MEDRTD018805SepsisDISEASEci_withergotamine tartrate
MEDRTD018805SepsisDISEASEci_withergotamine
MEDRTN0000000209Adrenergic alpha-AgonistsMOAhas_moaergotamine
MEDRTN0000000209Adrenergic alpha-AgonistsMOAhas_moaergotamine tartrate
MEDRTN0000190114Cytochrome P450 3A InhibitorsMOAhas_moaergotamine tartrate
MEDRTN0000190114Cytochrome P450 3A InhibitorsMOAhas_moaergotamine
MEDRTN0000182141Cytochrome P450 3A4 InhibitorsMOAci_moaergotamine
MEDRTN0000182141Cytochrome P450 3A4 InhibitorsMOAci_moaergotamine tartrate
MEDRTN0000000203Dopamine Receptor InteractionsMOAhas_moaergotamine tartrate
MEDRTN0000000203Dopamine Receptor InteractionsMOAhas_moaergotamine
MEDRTN0000000133Enzyme InhibitorsMOAhas_moacaffeine
MEDRTN0000000130Serotonin AntagonistsMOAhas_moaergotamine
MEDRTN0000000130Serotonin AntagonistsMOAhas_moaergotamine tartrate
MEDRTN0000008322BronchodilationPEhas_pecaffeine
MEDRTN0000008331Cardiovascular Activity AlterationPEhas_pecaffeine
MEDRTN0000008351Cerebral Arterial VasoconstrictionPEhas_peergotamine
MEDRTN0000008351Cerebral Arterial VasoconstrictionPEhas_peergotamine tartrate
MEDRTN0000008376Cutaneous Arterial VasoconstrictionPEhas_peergotamine tartrate
MEDRTN0000008567Decreased Collecting Duct Water PermeabilityPEhas_pecaffeine
MEDRTN0000009197Increased Central Nervous System Organized Electrical ActivityPEhas_pecaffeine
MEDRTN0000009705Increased Uterine Smooth Muscle Contraction or TonePEhas_peergotamine tartrate
MEDRTN0000009705Increased Uterine Smooth Muscle Contraction or TonePEhas_peergotamine

Properties#

Category, Property, Value table
CategoryPropertyValue
ATTRIBUTESGENERAL_CARDINALITYMULTI
ATTRIBUTESRXNAV_HUMAN_DRUGUS